IRIDEX Reports Strong Q4 & Full Year 2025 Results, Achieves First Positive Adjusted EBITDA in Recent History
IRIX sits 73% above its 52-week low of $0.79.
Summary
IRIDEX Corporation announced robust fourth-quarter and full-year 2025 financial results, highlighted by significant revenue growth, reduced net losses, and the achievement of positive adjusted EBITDA for the first time in recent company history.
Key Events · Earnings and Guidance · IRIX
-
Strong Revenue Growth
Q4 2025 revenue increased 16% year-over-year to $14.7 million, with full-year revenue growing 8% to $52.7 million.
-
Achieved Positive Adjusted EBITDA
The company reported positive adjusted EBITDA of $0.8 million for Q4 2025 and $1.1 million for the full year 2025, marking a significant operational milestone.
-
Reduced Net Loss
Net loss significantly improved to $0.2 million in Q4 2025 and $4.4 million for the full year, compared to larger losses in the prior year.
-
Cost Control
Operating expenses were reduced by 10% in Q4 and 22% for the full year 2025.
Analysis · IRIX · Industrial Applications And Services
This 8-K filing details IRIDEX's strong operational performance, which is critical for a micro-cap company. The company reported substantial year-over-year revenue growth in both Q4 and the full year 2025, alongside a significant reduction in net losses. Most notably, IRIDEX achieved positive adjusted EBITDA for the first time in recent history, signaling improved operational efficiency and a potential path to sustainable profitability. While gross margins declined due to increased manufacturing costs and tariffs, and 2026 revenue guidance is cautious due to geopolitical impacts, the overall financial health and operational trajectory show a positive shift. Investors should monitor the company's ability to maintain positive operating cash flow and manage gross margin pressures in 2026.
At the time of this filing, IRIX was trading at $1.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $0.79 to $1.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.